NYMC Faculty Publications

Lack of Genotoxicity Potential and Safety Assessment of 4-(2-Hydroxyethyl) Morpholine Present as an Impurity in Pharmaceuticals and Nutritional Supplements

Author Type(s)

Faculty

DOI

10.1016/j.fct.2023.114352

Journal Title

Food and Chemical Toxicology

First Page

114352

Document Type

Article

Publication Date

2-1-2024

Department

Pathology, Microbiology and Immunology

Abstract

4-(2-Hydroxyethyl) morpholine (HEM) is widely used as a building block of macromolecules in the manufacture of pharmaceuticals and dietary supplements and could remain as an impurity in the finished products. An evaluation of HEM was conducted to identify endpoints that could be used to determine the point-of-departure (POD) for use in assessing the potential risk from exposure to HEM. No oral repeated dose toxicological studies of appropriate duration were found for HEM. Therefore, suitable analogue(s) were identified. Although oral repeated dose studies were available for the analogues, the studies were not of sufficient duration for use in the assignment of a POD for risk evaluation. Accordingly, the Threshold of Toxicological Concern (TTC) approach, which proposes that a de minimis value can be derived to qualitatively assess risk, was considered for HEM. To determine the appropriate TTC approach (genotoxic or non-genotoxic), the genotoxicity of HEM and its analogues were evaluated. The weight of the evidence indicated that HEM, and the appropriate analogues, are not genotoxic. Considering the chemical structure of HEM, the non-genotoxic Cramer class III TTC value of 1.5 μg/kg bw/day was determined to be appropriate for use in safety assessment of HEM as an impurity in products intended for human consumption.

Link to Full Text

Share

COinS